ASCO 2020：11项我国研究入选口头报告，17项Poster报告

所受全球从新冠疫情严重影响，预定于5月底29日~6月底2日在底特律举行的美国临床学则会（ASCO）年则会今年将首次以线上形式举办，这是目前最大规模的线上嘉年华。今天，代表大则会的内容可题目揭晓，共103个sessions，中所国共有11项学术研究表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

酮类替尼或拉帕替尼加卡培他滨用于HER2+高血压乳腺胃癌（PHOEBE）：一项III期随机试验性。

演奏则会：高血压乳腺胃癌

笔记：中所国医学科学院的医院徐兵河大学教授、马飞大学教授，武汉大学附属的医院胡夕春大学教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性乳腺胃癌从新标准疗程后卡培他滨维系节拍化学治疗的III期试验性（SYSUCC-001）。

演奏则会：乳腺胃癌—渐进/范围/辅助疗程

笔记：中所山大学防疫中所心王树森大学教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用高血压脑组织的表型特质来预期脑组织脊液中所循环DNA检验的概率: 从新用以对抗据传对手

演奏则会：从新用以消除据传问题

笔记：李美芹 李德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

了了非尼对马利拉非尼作为早期肝细胞膜胃癌的中路疗程：一项闭馆表单、随机、多中所心II/III期试验性。

演奏则会：消化系统胃癌—胃食管、肾上腺和实无

笔记：重庆大学华西的医院毕锋大学教授、中所国老百姓解放军八一的医院秦叔逵大学教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中所国早期肝胃癌患者阿帕替尼二线疗程：一项随机、安慰剂对照、双盲III期学术研究

演奏则会：消化系统胃癌—胃食管、肾上腺和实无

笔记：中所国老百姓解放军八一的医院秦叔逵大学教授、重庆大学华西的医院李秋大学教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期发作性卵巢胃癌二次细胞膜减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

栏目：针灸肺乳癌

笔记：武汉大学附属中所山的医院臧荣余大学教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胃癌根治性子宫切除术后辅助疗程中所的序贯放化学治疗对比单独放疗或同步放化学治疗（STARS学术研究）：一项随机、对照、闭馆表单的III期试验性。

代表大则会：针灸肺乳癌

笔记：中所山大学防疫中所心大白大学教授、刘继红大学教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比化学治疗用于可切除的EGFR基因突变的N1-N2期NSCLC-随机III期临床试验性的最终总体生存归纳。

栏目：肺胃癌—非小细胞膜渐进-范围/小细胞膜/其他胸部

笔记：广东省老百姓的医院吴一龙大学教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因突变寡转到非小细胞膜肺胃癌患者中路丝氨酸还原酶抑制剂倡议或不倡议积极前线渐进放疗：III期闭馆表单临床随机试验性（SINDAS）的中所期结果（NCT02893332）。

栏目：肺胃癌-非小细胞膜转到

笔记：四川省老百姓的医院曾铭大学教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性死亡-1（PD-1）的人源化IgG4单克隆抗体倡议阿昔替尼用于高血压黏膜黑色素瘤患者的Ib期学术研究的总生存期和生物多种类型归纳。

栏目：黑色素瘤/皮肤胃癌

笔记：北京大学的医院郭军、盛锡楠大学教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的耐用性和结果：通用CAR-T细胞膜首次生理试验性疗程发作/难治性T细胞膜急性抗原膜胃癌（r/r T-ALL）的耐用性和。代表大则会：合作开发中所的疗程技术-免疫疗程。笔记：王欣欣等内容可：3013月底历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利他汀在早期食管柱状细胞膜胃癌患者中所的应用：一项随机的闭馆表单II期试验性（ORIENT-2）。代表大则会：消化系统胃癌-胃食管胃癌、肾上腺胃癌和实无道胃癌笔记：徐建明大学教授等内容可：4511月底历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T细胞膜对质母细胞膜瘤的消弭性疗程代表大则会：中所枢神经系统笔记：代红久、孙斌、杨东、徐晖、潘晶晶、魏佳、赵旭东内容可：2522月底历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复不足之处患者中所的应用代表大则会：合作开发中所的疗程学-免疫疗程笔记：沈琳大学教授等内容可：3021月底历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程发作/难治性ACUTE抗原膜胃癌/淋巴瘤的首例生理临床试验性代表大则会: 合作开发性疗程学-免疫疗程笔记简介：张明志，板桥乡等内容可：3026月底历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 科克替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议应用于早期实体瘤患者的Ib期学术研究代表大则会：发展性疗程学--分子靶向药物和生物学笔记：龚继芳，沈琳大学教授等内容可：3523月底历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议抗病毒和nedaplatin疗程发作性或高血压食管柱状细胞膜胃癌（ESCC）患者的II期学术研究。代表大则会：消化系统胃癌-胃食管、肾上腺和实无道胃癌的学术研究笔记：王志强于，李玉红，王德申，王凤华，任超，谭琼 王志强于、李玉红、王德深、王凤华、任超、谭琼内容可：4522月底历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.代表大则会：消化系统胃癌-胃食管胃癌、肾上腺胃癌和实无管胃癌的二线疗程笔记：宋艳等内容可：4524月底历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体外缘RNA分类器用于初始活检时检验高等级胃癌的分泌物外体外缘RNA分类器：一项多中所心的回顾性学术研究代表大则会：脊柱生殖肺乳癌---胃癌、睾丸胃癌和胃癌笔记简介：Liaoyuan Li等内容可：5522月底历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进早期宫颈胃癌并发化学治疗后的辅助化学治疗代表大则会: 针灸肺乳癌笔记简介： 李珉珉等内容可：6031月底历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺质性胃癌的相关性：基于ALTER01031试验性的归纳。则会话：皮脂腺笔记：天津的医院高深大学教授内容可：6526月底历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后患者结尾的严重影响: ALTER01031的亚组归纳代表大则会：皮脂腺笔记：天津的医院高深大学教授内容可：6527月底历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA归纳预期I-IIIA期非小细胞膜肺胃癌（NSCLC）患者术后发作: GASTO1035和GASTO1018的结果代表大则会：肺胃癌-非小细胞膜渐进-范围性/小细胞膜/小细胞膜/其他胸科肺乳癌笔记：Si-Yu Wang等内容可：9023月底历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞膜肺胃癌（NSCLC）中所EGFR丝氨酸还原酶抑制剂的从新型病毒性前提代表大则会:肺胃癌-非小细胞膜高血压肺胃癌笔记简介：赵昕，金玲玲，满宇，欧秋香，才与，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、才与、薛武、杨绍、范敏内容可：9528月底历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性前期黑色素瘤总生存的替代终点站代表大则会：黑色素瘤/皮肤胃癌笔记：聂润聪，袁书强于，李元芳，陈英波，周志伟 聂润聪、袁书强于、李元芳、陈英波、周志伟内容可：10030月底历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程发作或高血压继发性恶性骨患者的II期学术研究代表大则会： 遗传性笔记：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525月底历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在早期遗传性患者多线疗程中所的耐用性和。代表大则会：遗传性笔记：姚伟涛，王家强于，姚，王欣，杜从新辉，田志浩，牛晓颖 姚伟涛、王家强于、姚、王鑫、杜鑫辉、田志超、牛晓英内容可：11526月底历：414